Cytokine Release Syndrome

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Pre-emptive Anakinra for Cytokine Event Reduction

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Jafron Haemoadsorption During Cardiopulmonary Bypass

Anakinra in the Management of COVID-19 Infection

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19